Comera Life Sciences Holdings, Inc. (CMRA) 10K Annual Reports & 10Q SEC Filings

– Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) –

– Joined the Subcutaneous Drug Development & Delivery Consortium (SC Consortium) to advance the science, technology, and best practices for subcutaneous (SQ) drug development and delivery –

WOBURN, Mass.—March 16, 2023—

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

“During 2022, Comera generated significant momentum, strengthening of the Company’s capabilities, team, proprietary pipeline, and executing pharmaceutical partnerships to drive value for Comera shareholders and our partners. These accomplishments have positioned Comera to achieve substantial progress across our business,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. “As we continue to execute on our goals and drive our value proposition, we are bolstered by our mission to transform the patient experience. Our novel technology and deep experience in protein formulation has the potential to transform the delivery of biologics from intravenous to subcutaneous form enabling people to self-medicate at home and ultimately reduce healthcare costs, improving quality of life. ”

Recent Business Highlights

•

Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company. The partnership includes a right to negotiate a license after further technical evaluation is complete.

•

Announced its lead pipeline candidate CLS-001 as a SQ formulation of vedolizumab, a currently marketed product for the treatment of IBD including Crohn’s disease and ulcerative colitis. Comera believes that a SQ formulation of vedolizumab could have significant advantages for patients and the healthcare system, compared to the current intravenous (IV) formulation.

The following information was filed by Comera Life Sciences Holdings, Inc. (CMRA) on Thursday, March 16, 2023 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

ChatGPT says Comera Shifts Focus to High-Value Partnerships, Raises Funds.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1907685/000095017023008654/cmra-20221231.htm

View differences made from one year to another to evaluate Comera Life Sciences Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Comera Life Sciences Holdings, Inc..

Continue

Assess how Comera Life Sciences Holdings, Inc.'s management team is paid from their Annual Proxy

Comera Life Sciences Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

M & A

Other

Filter Subcategory:

All

Expense

Product

Income

Other

Inside Comera Life Sciences Holdings, Inc.'s 10-K Annual Report:

Financial - Expense Highlight
Our noncash adjustments were primarily comprised of $6.6 million related to stock issuance costs in excess of gross proceeds associated with the Transaction and a $1 million private placement of our common stock entered into with Maxim Group LLC immediately prior to the Transaction (the Maxim Private Placement) and $650 thousand related to noncash common stock issuance costs related to the Arena Purchase Agreement, partially offset by $2.0 million decrease in fair value of the derivative warrant liabilities.

Other - Other Highlight
We will receive up to an aggregate of $127.0 million if all of the outstanding Public Warrants and $5.9 million if all of the outstanding 2023 PIPE Warrants are exercised for cash.
Revenue - Product Highlight
Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful development and eventual licensing and/or commercialization of one or more of our current or future pipeline programs as well as continued successful execution of pharmaceutical research collaborations and subsequent execution of collaboration programs.
Financial - Expense Highlight
These expenses were partially offset by a $2.0 million decrease in fair value of the Companys derivative warrant liabilities which were assumed in the Transaction.
Financial - Income Highlight
Other Income (Expense), Net For the year ended December 31, 2022, total other expense, net of $6.0 million was primarily comprised of $6.6 million expense related to stock issuance costs which exceeded the net tangible assets received from the Transaction, $1.0 million expense related to the Arena Purchase Agreement (the Arena Purchase Agreement), and a $590 thousand loss from payments related to a business email compromise fraud which resulted in a diversion of the Companys capital to unknown parties which was partially offset by $164 thousand of insurance proceeds for a net loss of $426 thousand.
Financial - Expense
The increase of $49 thousand...Read more
Financial - Expense
These expenses include: expenses incurred...Read more
Financial - Expense
We anticipate the additional costs...Read more
Revenue - Product
Because these research and development...Read more
Financial - Expense
The decrease of $13 thousand...Read more
Financial - Expense
Reimbursements from and payments to...Read more
Financial - Expense
In addition, we expect our...Read more
Financial - Expense
In addition, costs include allocated...Read more
Revenue - Product
To achieve this core principle,...Read more
Other - Other
Known Trends, Events and Uncertainties...Read more
Other - Other
Performance obligations promised in a...Read more
Revenue - Product
The amount of revenue recognized...Read more
Other - Other
Upon the execution of the...Read more
Revenue - Product
For contracts or units of...Read more
Other - Other
To the extent a contract...Read more
Financial - Expense
Our noncash adjustments were primarily...Read more
Other - Other
Upon completion of the project,...Read more
Revenue - Product
If we raise additional funds...Read more
Financial - Income
For the year ended December...Read more
Financial - Expense
We recognize external development costs...Read more
Financial - Expense
The net cash inflows associated...Read more
Revenue - Product
We generally expect revenue to...Read more
M & A - Other
If an arrangement is determined...Read more
Financial - Expense
If successful, this transformation in...Read more
M & A - Other
On May 19, 2022, we...Read more
Financial - Shares
Under the reverse recapitalization model,...Read more
Financial - Expense
We expect that our research...Read more
Other - Other
If these criteria are not...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Comera Life Sciences Holdings, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 4: Instruments Defining The Rights Of Security Holders, Including Indentures

Exhibit 10: Material Contract

Exhibit 23: Consents Of Experts And Counsel

Exhibit 31: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32: Section 1350 Certification

Ticker: CMRA
CIK: 1907685
Form Type: 10-K Annual Report
Accession Number: 0000950170-23-008654
Submitted to the SEC: Fri Mar 17 2023 4:32:07 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations